Screening for autoimmune type 1 diabetes (T1D)

How early can autoimmune type 1 diabetes be detected?

Autoimmune type 1 diabetes (T1D) is a lifelong condition with a progressive nature, 1 which is often diagnosed only after ​​symptoms appear. 2 Many people, especially children under 18 years old, find out about their condition only after a medical emergency. 2–4


Nowadays, screening tests exist that allow us to catch ​​autoimmune type 1 diabetes early, providing the opportunity to get ahead of ​​complications and prepare for life with the condition. 4-5

What is autoimmune type 1 diabetes screening?

Autoimmune type 1 diabetes develops over time when the body’s immune system mistakenly attacks the insulin-producing cells of the pancreas (beta cells). 1 A type of molecule produced by the immune system, called autoantibodies, is involved in this attack; autoantibodies appear months or years before the symptoms of the disease. 5,6


Learn more about ​how autoimmune type 1 diabetes works in the body.


Screening for autoimmune type 1 diabetes can be done with a blood test, usually from a vein in the arm or from a fingertip, that identifies these antibodies. 2,6,7 This is different from a blood glucose level test.


When a person has two or more type 1 diabetes autoantibodies in the blood, they are likely to develop autoimmune type 1 diabetes.1,8

What autoantibodies are present in autoimmune type 1 diabetes?

Autoimmune type 1 diabetes screening will check the presence of four different type 1 diabetes autoantibodies in the blood: 6,9


These autoantibodies appear one after the other, not at the same time, during the development of the condition, and can be found in the blood in different combinations. 6,10

Who should get autoimmune type 1 diabetes screening?

For a long time, autoimmune type 1 diabetes has been considered a childhood condition. 11,12 Now it is known that anyone at any age can get autoimmune type 1 diabetes, although people younger than 35 years are more likely to develop this condition. 8,11


Many factors may increase the likelihood of getting autoimmune type 1 diabetes, for example:

  • Having a relative with autoimmune type 1 diabetes
  • Having a personal or family history of other autoimmune conditions, such as celiac or thyroid disease. 9,13


People with a parent or a sibling with autoimmune type 1 diabetes are recommended to get an autoantibody screening for type 1 diabetes, since they have a 15 times higher chance (15-fold) of developing this condition than others. 2,10,13


However, most people with autoimmune type 1 diabetes do not have any family history; this means that everyone can develop the condition, especially if they have high blood glucose, low body mass index, and are younger than 35. 9,14


Type 1 diabetes autoantibodies usually appear before the age of 6 years. 13,15 Screening for autoimmune type 1 diabetes should be done early in life, ideally at 2 years of age and then at 6 years of age, to improve the chance of early detection. 13, 16


Sometimes, prediabetes and type 2 diabetes can look similar to autoimmune type 1 diabetes, so getting screened is useful to confirm that someone with high blood glucose does not have autoimmune type 1 diabetes, or it may indicate that they are likely to develop it in the future. 9,10


Learn more about the ​misdiagnosis of autoimmune type 1 diabetes.

How to get autoimmune type 1 diabetes screening?

Different autoimmune type 1 diabetes screening programs can be available in different areas. 2,9 ​Depending on where you live, you or your child’s doctor can order labs to detect type 1 diabetes autoantibodies, and your insurance may cover this . Your child’s doctor will recommend the best autoimmune T1D screening option for you among those available.


If type 1 diabetes autoantibodies are found in the first screening test, the test should be repeated 3 months later to confirm the result. 10 If T1D autoantibodies are not found in the second test, it is important that you monitor the appearance of potential autoimmune type 1 diabetes symptoms. 10,13

What do the results of type 1 diabetes autoantibody screening mean?

The screening test can give different results, each one suggesting a different course of action:

  • If none of the autoantibodies for type 1 diabetes are found in the blood sample, your doctor may suggest having an annual screening for autoimmune type 1 diabetes. 13
  • If 1 autoantibody is found, the person is likely to develop autoimmune type 1 diabetes in the future, and the doctor will suggest monitoring blood glucose levels; at this stage, there are no symptoms of autoimmune type 1 diabetes. 2,10
  • If 2 or more autoantibodies for type 1 diabetes are found, the person is highly likely to have presymptomatic Stage 1 or 2 autoimmune type 1 diabetes; another blood sample will be collected, and the autoantibody test will be repeated to confirm the result. 9,10


​​A person with Stage 1 or Stage 2 autoimmune type 1 diabetes does not show any symptoms but type 1 diabetes autoantibodies are already detectable in their blood. During Stage 3, the ​​signs and symptoms of autoimmune type 1 diabetes are already present. 2,9

What are the benefits of detecting autoimmune type 1 diabetes early?

Anyone can get an autoantibody screening for type 1 diabetes. The early detection of autoimmune type 1 diabetes through screening has many benefits:

  • Reduces the chance of a medical emergency
  • Allows for tracking autoimmune type 1 diabetes proactively through glucose monitoring
  • Provides more time to prepare for living with autoimmune type 1 diabetes. 2,5,14,17


Early diagnosis also provides the opportunity for education and support to people with autoimmune type 1 diabetes and their families, helping them feel as comfortable and informed as possible throughout the progression of the condition. 2 On the other hand, screening can provide relief and reassurance if type 1 diabetes autoantibodies are not detected. 2


​​

How do I get screened for autoimmune type 1 diabetes (T1D)?

Autoantibody screening for autoimmune T1D involves a finger prick or blood draw. You can have this done at a clinic or you can test yourself at home [local markets to adapt as necessary].18,19


You or a loved one may be eligible to access autoimmune T1D screening through the [insert trial name] trial, or by visiting [insert website name]: [insert website URL].

Abbreviations

T1D, type 1 diabetes.

References

  1. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi:10.2337/dc15-1419
  2. Scheiner G, Weiner S, Kruger DF, Pettus J. Screening for Type 1 Diabetes: Role of the Diabetes Care and Education Specialist. ADCES Pract. 2022;10(5):20-25. doi:10.1177/2633559X221110216
  3. Duca LM, Wang B, Rewers M, Rewers A. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control. Diabetes Care. 2017;40(9):1249-1255. doi:10.2337/dc17-0558
  4. Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347-2352. doi:10.2337/dc11-1026
  5. Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-1404. doi:10.2337/diacare.27.6.1399
  6. Yu L, Zhao Z, Steck AK. T1D Autoantibodies: room for improvement? Curr Opin Endocrinol Diabetes Obes. 2017;24(4):285. doi:10.1097/MED.0000000000000348
  7. Wentworth JM, Sing ABE, Naselli G, et al. Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen. Diabetes Care. 2025;48(4):556-563. doi:10.2337/dc24-2443
  8. Simmons KMW, Frohnert BI, O’Donnell HK, et al. Historical Insights and Current Perspectives on the Diagnosis and Management of Presymptomatic Type 1 Diabetes. Diabetes Technol Ther. 2023;25(11):790-799. doi:10.1089/dia.2023.0276
  9. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002
  10. Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024;67(9):1731-1759. doi:10.1007/s00125-024-06205-5
  11. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet. 2001;358(9277):221-229. doi:10.1016/S0140-6736(01)05415-0
  12. Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-760. doi:10.1016/S2213-8587(22)00218-2
  13. Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. J Pers Med. 2023;13(3):422. doi:10.3390/jpm13030422
  14. Sims EK, Besser REJ, Dayan C, et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022;71(4):610-623. doi:10.2337/dbi20-0054
  15. Greenbaum CJ. A Key to T1D Prevention: Screening and monitoring relatives as part of clinical care. Diabetes. 2021;70:1029–1037. doi:10.2337/db20-1112
  16. Ghalwash M, Dunne JL, Lundgren M, et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2022;10(8):589-596. doi:10.1016/S2213-8587(22)00141-3
  17. Simmons KM and Sims EK. Screening and prevention of type 1 diabetes: Where are we? J Clin Endocrinol Metab. 2023;108(12):3067-3079. doi:10.1210/clinem/dgad328
  18. Sims EK, Besser REJ, Dayan C, et al. Diabetes. 2022;71(4):610-623.
  19. Besser REJ, Bell KJ, Couper JJ, et al. Pediatr Diabetes. 2022;23(8):1175-1187.


[Approval date] | [Approval code]